2023
Implications of Immunotherapy for Pediatric Malignancies: A Summary from the APSA Cancer Committee
Talbot L, Lautz T, Aldrink J, Ehrlich P, Dasgupta R, Mattei P, Tracy E, Glick R, Grant C, Brown E, Christison-Lagay E, Rodeberg D. Implications of Immunotherapy for Pediatric Malignancies: A Summary from the APSA Cancer Committee. Journal Of Pediatric Surgery 2023, 58: 2119-2127. PMID: 37550134, DOI: 10.1016/j.jpedsurg.2023.07.001.Peer-Reviewed Original ResearchAPSA Cancer CommitteeClass of immunotherapyT-cell therapyCancer CommitteePediatric malignanciesChimeric antigen receptor T-cell therapyMonoclonal antibody checkpoint inhibitorsTransgenic T cell receptorBispecific T-cell engagersCell therapyEarly phase clinical trialsYoung adultsConventional chemotherapeutic regimensDisease-related deathT-cell engagersClass of therapyT cell receptorCare of childrenCheckpoint inhibitorsAdverse eventsMetastatic diseaseSystemic treatmentChemotherapeutic regimensSurgical interventionClinical trials
2019
p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors
Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson F, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Malouf G, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar A, Netto G, Rao P, Sgambato A, Maitra A, Tripathi D, Walker C, Karam J, Heffernan T, Viale A, Roberts C, Msaouel P, Tannir N, Draetta G, Genovese G. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell 2019, 35: 204-220.e9. PMID: 30753823, PMCID: PMC7876656, DOI: 10.1016/j.ccell.2019.01.006.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsAutophagyCell Line, TumorCyclin-Dependent Kinase Inhibitor p16Endoplasmic Reticulum StressFemaleGene Expression Regulation, NeoplasticHumansMaleMice, 129 StrainMice, Inbred C57BLMice, KnockoutProteasome InhibitorsProteostasisProto-Oncogene Proteins c-mycRhabdoid TumorSignal TransductionSMARCB1 ProteinTumor Cells, CulturedTumor Suppressor Protein p53Unfolded Protein ResponseConceptsMalignant rhabdoid tumorRhabdoid tumorUnfolded protein responseClinical pathological featuresAggressive pediatric malignancyCombination of agentsPediatric malignanciesMouse modelP53 axisMosaic mouse modelChromatin remodeling genesER stress responseTumorsHuman oncogenesisBiallelic inactivationMalignancyProtein responseDramatic activationHuman diseasesMaster regulatorExquisite sensitivityAutophagic machineryAgentsDiseaseStress response
2015
The Role of Registries and Tumor Banking in Rare Pediatric Tumors
Pashankar F, Bisogno G, Ribeiro R, Messinger Y, Schultz K, Rodriguez-Galindo C. The Role of Registries and Tumor Banking in Rare Pediatric Tumors. Current Pediatrics Reports 2015, 3: 128-136. DOI: 10.1007/s40124-015-0077-9.Peer-Reviewed Original ResearchRare pediatric tumorTumor RegistryRare tumorPediatric tumorsDevelopment of registriesRole of registriesTypes of registriesTherapeutic guidelinesPediatric malignanciesCo-operative groupsSingle tumorMolecular pathogenesisRegistryHeterogenous groupTumorsOrphan diseaseTissue repositoryUnderstanding carcinogenesisTumor bankingGroupMalignancyPathogenesisDisease
2013
Pediatric thymomas: report of two cases and comprehensive review of the literature
Fonseca AL, Ozgediz DE, Christison-Lagay ER, Detterbeck FC, Caty MG. Pediatric thymomas: report of two cases and comprehensive review of the literature. Pediatric Surgery International 2013, 30: 275-286. PMID: 24322668, DOI: 10.1007/s00383-013-3438-x.Peer-Reviewed Original ResearchConceptsStage diseaseSurgical excisionRare pediatric malignancyMasaoka stage IEarly-stage diseaseSlight male predominanceTreatment of thymomaLate-stage diseaseMulti-institutional studyPediatric thymomaAdjuvant therapyClinical courseMyasthenia gravisPrognostic factorsMale predominanceIndolent behaviorPediatric malignanciesRare tumorCase reportReference listsStage IIIThymomaStage IStage IVPubMed database
2012
A Review of Secondary Central Nervous System Tumors After Treatment of a Primary Pediatric Malignancy
Marks AM, Packer RJ. A Review of Secondary Central Nervous System Tumors After Treatment of a Primary Pediatric Malignancy. Seminars In Pediatric Neurology 2012, 19: 43-48. PMID: 22641075, DOI: 10.1016/j.spen.2012.02.015.Peer-Reviewed Original ResearchConceptsCentral nervous system tumorsSecondary central nervous system tumorsNervous system tumorsPediatric malignanciesSystem tumorsPrimary brain tumorsRole of treatmentCancer predisposition syndromeTreatment of leukemiaSecondary malignanciesSecondary tumorsBrain tumorsPredisposition syndromeMalignancyTumorsTreatmentRemarkable stridesSyndromeEtiologyLeukemiaIncidenceDiagnosis
2011
Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia
Jemal A, Tyner J, Thayer M, Muschen M, Druker B, Chang B. Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia. Blood 2011, 118: 2490. DOI: 10.1182/blood.v118.21.2490.2490.Peer-Reviewed Original ResearchPediatric acute lymphoblastic leukemiaAcute lymphoblastic leukemiaLymphoblastic leukemiaPatient samplesPrimary patientsCell linesActivation of apoptosisPediatric B-cell precursorHematopoietic stem cell transplantSelective survivin suppressantStandard intensive chemotherapyEarly phase I studiesSubset of patientsStem cell transplantPhase I studiesCommon pediatric malignancyB-cell malignanciesPrimary patient samplesB cell precursorsLymphoblastic cell linesAdditional therapyIntensive chemotherapyCell transplantCombination therapyPediatric malignancies
1988
On the value of response criteria in therapeutic research.
Devita V. On the value of response criteria in therapeutic research. Bulletin Du Cancer 1988, 75: 863-9. PMID: 3061500.Peer-Reviewed Original ResearchConceptsLocal tumor presentationPrimary chemotherapyTumor presentationBiological marker of responseResponse to primary chemotherapySmall-cell lung cancerDiffuse large-cell lymphomaResponse criteriaLarge-cell lymphomaComplete remission rateRelapse-free survivalFull dose chemotherapyPrimary tumor massMarkers of responseCytoreductive effectInduction chemotherapyDose chemotherapyRemission ratePediatric malignanciesTumor massPrimary treatmentChemotherapyLung cancerInduction cyclesAlternative therapies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply